A Tiny Biotech Startup Wages War Against AIDS

One of the most promising attacks on the dread disease was produced far from the meccas of biotechnology The message transmitted from the fourth International Conference on AIDS in Stockholm this June was bleak. Seven thousand of the world’s leading scientists had gathered to hear more than 3,100 presentations and to discuss what has been learned about the virus. “Not enough” was the answer. An estimated five million to 10 million people have been infected with the HIV virus,

David Graham
Aug 7, 1988
One of the most promising attacks on the dread disease was produced far from the meccas of biotechnology

The message transmitted from the fourth International Conference on AIDS in Stockholm this June was bleak. Seven thousand of the world’s leading scientists had gathered to hear more than 3,100 presentations and to discuss what has been learned about the virus. “Not enough” was the answer. An estimated five million to 10 million people have been infected with the HIV virus, one million of these United States citizens. And, though scientific knowledge and understanding of the virus is expanding, little progress has been made over the past year toward a vaccine or effective treatment. But amidst the pessimism and gloom, a small poster display struck a rare, optimistic note. It showed clinical test results of a proposed therapeutic that appears to be effective in slowing the ravages of the wasting disease.

Each...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?